Latest News
Tiziana Life Sciences Announces Online Publication of Two Abstracts at ASCO Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma
14 May 2020
Online Publication of Two Abstracts at ASCO Reporting Clinical Activity and Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma
ASCO Abstract 2: Comparison of StemPrintER with Oncotype DX in the TransATAC cohort.
14 May 2020
Comparison of StemPrintER, a Novel Biology-based Genomic Predictor of Distant Recurrence in Breast Cancer, with Oncotype DX in the TransATAC cohort.
ASCO Abstract 1: Integration of StemPrintER with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2-
14 May 2020
Integration of the stem cell biology-based genomic tool, StemPrintER, with clinicopathological parameters for the prediction of distant recurrence in ER+/HER2- breast cancer patients.
Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to OncotypeDX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at ASCO
14 May 2020
StemPrintER’s Superiority Compared to OncotypeDX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients
TR-1: Standard form for notification of major holdings
11 May 2020
|
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i |
||||||
| ... |
Tiziana Life Sciences to present two studies featuring StemPrintER, a stem cell biology-based Breast Cancer Prognostic Tool during the American Society of Clinical Oncology (ASCO) Virtual Conference
11 May 2020
Two additional abstracts featuring Milciclib in treating Hepatocellular Carcinoma to be published online
New York/London – May 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune...